{"efta_number": "EFTA00621382", "page_count": 5, "url": "https://epstein-data.com/EFTA00621382", "pdf_url": "https://epstein-data.com/pdf/EFTA00621382.pdf", "pages": [{"efta_number": "EFTA00621382", "page_number": 0, "text_content": "libj Quest \nDiagnostics \nReport Status: Final \nEPSTEIN, JEFFREY \nPatient Information \nEPSTEIN, JEFFREY \nDOB: 01/20/1953 \nAGE: 64 \nGender: \nM \nSpecimen: \nMR624132A \nRequisition: 0002759 \nCollected: \n08/09/2017 \nPhone: \n561.366.0084 \nReceived: \n08/14/2017 108:51 EDT \nPatient ID: 19530120MJE \nReported: \n08/14/2017 108:51 EDT \nHealth ID: 8573003290851249 \nSpecimen Information \nClient Information \nTeat Name \nLIPID PANEL \nCHOLESTEROL, TOTAL \nHDL CHOLESTEROL \nTRIGLYCERIDES \nLDL-CHOLESTEROL \nIn Range \nOut Of \n211 H \n25 L \n532 H \nRange \nLDL cholesterol not calculated. Triglyceride levels \ngreater than 400 mg/dL invalidate calculated LDL results. \nDesirable range <100 mg/dL for patients with CHD or \ndiabetes and <70 mg/dL for diabetic patients with \nknown heart disease. \nCHOL/HDLC RATIO \n8.4 H \nNON HDL CHOLESTEROL \n186 H \nTarget for non-HDL cholesterol is 30 mg/dL higher than \nLDL cholesterol target. \nHS CRP \n0.8 \nLower relative cardiovascular risk according to \nAHA/CDC guidelines. \nFor ages >17 \nhs-CRP mg/L \n<1.0 \n1.0-3.0 \n3.1-10.0 \n>10.0 \nYears: \nRisk According to AHA/CDC Guidelines \nLower relative cardiovascular risk. \nAverage relative cardiovascular risk. \nHigher relative cardiovascular risk. \nConsider retesting in 1 to 2 weeks to \nexclude a benign transient elevation \nin the baseline CRP value secondary \nto infection or inflammation. \nPersistent elevation, upon retesting, \nmay be associated with infection and \ninflammation. \nClient #: 78300020 \n56W5265 \nMOSKOWITZ, BRUCE W \nBRUCE MOSKOWITZ, MD \nAttn: NATIONWIDE ACCOUNT \n1411 N FLAGLER DR STE 7100 \nWEST PALM BEACH, FL 33401-3418 \nReference Range \n125-200 mg/dL \n> OR = 40 mg/dL \n<150 mg/dL \n<130 mg/dL (talc) \n< OR = 5.0 (talc) \nmg/dL (talc) \nmg/L \nHONOCYSTEINE \n15.4 B \n<11.4 umol/L \nHomocysteine is increased by functional deficiency of \nfolate or vitamin B12. Testing for methylmalonic acid \ndifferentiates between these deficiencies. Other causes \nof increased homocysteine include renal failure, folate \nantagonists such as methotrexate and phenytoin, and \nexposure to nitrous oxide. \nCOMPREHENSIVE METABOLIC \nPANEL \nGLUCOSE \n94 \n65-99 mg/dL \nFasting reference \nUREA NITROGEN (BUN) \n19 \nCREATININE \n1.06 \nFor patients >49 years of age, the reference limit \ninterval \n7-25 mg/dL \n0.70-1.25 mg/dL \nLab \nMI \nMI \nMI \nMI \nMI \nMI \nTP \nMI \nMI \nCLIENT SERVICES: 866.697.8378 \nSPECIMEN: MR624132A \nQuest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. \nPAGE I OF 5 \nEFTA00621382\n", "char_count": 2521}, {"efta_number": "EFTA00621382", "page_number": 1, "text_content": "Quest \nDiagnostics \nReport Status: Final \nEPSTEIN, JEFFREY \nPatient Information \nSpecimen Information \nClient Information \nEPSTEIN, JEFFREY \nDOB: 01/20/1953 \nAGE: 64 \nGender: \nM \nPatient ID: 19530120MJE \nHealth ID: 8573003290851249 \nSpecimen: \nMR624132A \nCollected: \n08/09/2017 \nReceived: \n08/14/2017 /08:51 EDT \nReported: \n08/14/2017 / 08:51 EDT \nClient #: 78300020 \nMOSKOWITZ. BRUCE W \nTest Name \nIn Range \nOut Of Range \nfor Creatinine is approximately 13% higher for people \nReference Range \nLab \nidentified as African-American. \neGFR NON-AFR. AMERICAN \n74 \neGFR AFRICAN AMERICAN \n86 \n> OR = 60 mL/min/1.73m2 \n> OR = 60 mL/min/1.73m2 \nBUN/CREATININE RATIO \nNOT APPLICABLE \n6-22 (calc) \nSODIUM \n138 \n135-146 mmol/L \nPOTASSIUM \n4.3 \n3.5-5.3 mmol/L \nCHLORIDE \n107 \n98-110 mmol/L \nCARBON DIOXIDE \n23 \n20-31 mmol/L \nCALCIUM \n9.5 \n8.6-10.3 mg/dL \nPROTEIN, TOTAL \n6.7 \n6.1-8.1 g/dL \nALBUMIN \n4.2 \n3.6-5.1 g/dL \nGLOBULIN \n2.5 \n1.9-3.7 g/dL (calc) \nALBUMIN/GLOBULIN RATIO \n1.7 \n1.0-2.5 (calc) \nBILIRUBIN, TOTAL \n0.8 \n0.2-1.2 mg/dL \nALKALINE PHOSPHATASE \n57 \n40-115 U/L \nAST \n22 \n10-35 U/L \nALT \n33 \n9-46 U/L \nHEMOGLOBIN Ale \n5.7 B \n<5.7 % of total Hgb \nMI \nFor someone without known diabetes, a hemoglobin \nAle value between 5.7% and 6.4% is consistent with \nprediabetes and should be confirmed with a \nfollow-up test. \nFor someone with known diabetes, a value <7% \nindicates that their diabetes is well controlled. Ale \ntargets should be individualized based on duration of \ndiabetes, age, comorbid conditions, and other \nconsiderations. \nThis assay result is consistent with an increased risk \nof diabetes. \nCurrently, no consensus exists regarding use of \nhemoglobin Ale for diagnosis of diabetes for children. \nURIC ACID \nTherapeutic target \nTSH \nT4 (THYROXINE), TOTAL \nFREE T4 INDEX (T7) \n6.9 \nfor gout patients: <6.0 mg/dL \n4.17 \n7.1 \n2.1 \nT3 UPTAKE \n30 \nSED RATE BY MODIFIED \nWESTERGREN \n9 \nCBC (INCLUDES DIFF/PLT) \nWHITE BLOOD CELL COUNT \n6.0 \nRED BLOOD CELL COUNT \n5.37 \nHEMOGLOBIN \n15.0 \nHEMATOCRIT \n45.2 \nMCV \n84.2 \nMCH \n27.9 \nMCHC \n33.2 \nRDW \n14.3 \nPLATELET COUNT \n281 \nCLIENT SERVICES: 866.697.8378 \nSPECIMEN: MR624132A \n4.0-8.0 mg/dL \n0.40-4.50 mIU/L \n4.5-12.0 mcg/dL \n1.4-3.8 \n22-35 % \n< OR = 20 mm/h \n3.8-10.8 Thousand/uL \n4.20-5.80 Million/uL \n13.2-17.1 g/dL \n38.5-50.0 % \n80.0-100.0 fL \n27.0-33.0 pg \n32.0-36.0 g/dL \n11.0-15.0 % \n140-400 Thousand/uL \nMI \nMI \nMI \nMI \nMI \nMI \nPAGE 2 OF 5 \nQuest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. \nEFTA00621383\n", "char_count": 2544}, {"efta_number": "EFTA00621382", "page_number": 2, "text_content": "ab) Quest \nDiagnostics \nReport Status: Final \nEPSTEIN, JEFFREY \nPatient Information \nSpecimen Information \nClient Information \nEPSTEIN, JEFFREY \nDOB: 01/20/1953 \nAGE: 64 \nGender: \nM \nPatient ID: 19530120MJE \nHealth ID: 8573003290851249 \nSpecimen: \nMR624132A \nCollected: \n08/09/2017 \nReceived: \n08/14/2017 108:51 EDT \nReported: \n08/14/2017 108:51 EDT \nClient #: 78300020 \nMOSKOWITZ, BRUCE W \nTest Name \nIn Range \nMPV \n9.7 \nABSOLUTE NEUTROPHILS \n2664 \nABSOLUTE LYMPHOCYTES \n2304 \nABSOLUTE MONOCYTES \n510 \nABSOLUTE EOSINOPHILS \n450 \nABSOLUTE BASOPHILS \n72 \nNEUTROPHILS \n44.4 \nLYMPHOCYTES \n38.4 \nMONOCYTES \n8.5 \nEOSINOPHILS \n7.5 \nBASOPHILS \n1.2 \nURINALYSIS, COMPLETE \nSee Endnote 2 \nVITAMIN B12 \n439 \nC-REACTIVE PROTEIN \n0.12 \nOut Of Range \nReference Range \n7.5-12.5 fL \n1500-7800 cells/uL \n850-3900 cells/uL \n200-950 cells/uL \n15-500 cells/uL \n0-200 cells/uL \n200-1100 pg/mL \n<0.80 mg/dL \nPlease be advised that patients taking Carboxypenicillins \nmay exhibit falsely decreased C-Reactive Protein levels \ndue to an analytical interference in this assay. \nCORTISOL, TOTAL \nReference Range: For \nReference Range: For \n* Please interpret \n20 2 \nmcg/dL \n8 \n.(7-9 \n.) Specimen: 4.0-22.0 \n4 \n.(3-5 \n.) Specimen: 3.0-17.0 \nabove results accordingly * \nTESTOSTERONE, TOTAL \nMALES (ADULT), IA \nTESTOSTERONE, TOTAL, \nMALES (ADULT), IA \n197 L \nMen with clinically significant hypogonadal symptoms \nand testosterone values repeatedly less than \napproximately 300 ng/dL may benefit from testosterone \ntreatment after adequate risk and benefits counseling. \nIn hypogonadal males, Testosterone, Total, LC/MS/MS, \nis the recommended assay due to the diminished \naccuracy of immunoassay at levels below 250 ng/dL. \nThis test code (15983) must be collected in a \nred-top tube with no gel. Two morning (8-10 III.) \nspecimens obtained on different days are recommended \nby The Endocrine Society for screening for \nhypogonadism. \nPSA, TOTAL \n0.5 \nThe total PSA value from this assay system is \nstandardized against the WHO standard. The test \nresult will be approximately 20% lower when compared \nto the equimolar-standardized total PSA (Beckman \nCoulter). Comparison of serial PSA results should be \ninterpreted with this fact in mind. \nThis test was performed using the Siemens \nchemiluminescent method. Values obtained from \ndifferent assay methods cannot be used \ninterchangeably. PSA levels, regardless of \nvalue, should not be interpreted as absolute \nevidence of the presence or absence of disease. \nEndnote I \n1*** ******************* \n**Irtt**Ortt** \n* Test not performed. \n250-827 ng/dL \n< OR = 4.0 ng/mL \nLab \nMI \nMI \nMI \nMI \nMI \nMI \nCLIENT SERVICES: 866.697.8378 \nSPECIMEN: MR624132A \nQuest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. \nPAGE30F5 \nEFTA00621384\n", "char_count": 2827}, {"efta_number": "EFTA00621382", "page_number": 3, "text_content": "rajQuest \nDiagnostics \nReport Status: Final \nEPSTEIN, JEFFREY \nPatient Information \nSpecimen Information \nClient Information \nEPSTEIN, JEFFREY \nDOB: 01/20/1953 \nAGE: 64 \nGender: \nM \nPatient ID: 19530120MJE \nHealth ID: 8573003290851249 \nSpecimen: \nMR624132A \nCollected: \n08/09/2017 \nReceived: \n08/14/2017 / 08:51 EDT \nReported: \n08/14/2017 108:51 EDT \nClient #: 78300020 \nMOSKOWITZ. BRUCE W \n* No urine received. \n* \nCLIENT SERVICES: 866.697.8378 \nSPECIMEN: MR624132A \nPAGE 4 OF 5 \nQuest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. \nEFTA00621385\n", "char_count": 625}, {"efta_number": "EFTA00621382", "page_number": 4, "text_content": "rajQuest \nDiagnostics \nReport Status: Final \nEPSTEIN, JEFFREY \nPatient Information \nSpecimen Information \nClient Information \nEPSTEIN, JEFFREY \nDOB: 01/20/1953 \nAGE: 64 \nGender: \nM \nPatient ID: 19530120MJE \nHealth ID: 8573003290851249 \nSpecimen: \nMR624132A \nCollected: \n08/09/2017 \nReceived: \n08/14/2017 /08:51 EDT \nReported: \n08/14/2017 / 08:51 EDT \nClient #: 78300020 \nMOSKOWITZ. BRUCE W \nEndocrinology \nTest Name \nResult \nReference Range \nLab \nVITAMIN D,25.OH,TOTAL,IA \n35 \n30-100 ng/mL \nMI \nVitamin D Status \nDeficiency: \nInsufficiency: \nOptimal: \n25-OH Vitamin D: \n<20 ng/mL \n20 - 29 ng/mL \n> or = 30 ng/mL \nFor 25-OH Vitamin D testing on patients on \nD2-supplementation and patients for whom quantitation \nof D2 and D3 fractions is required, the QuestAssureD(TM) \n25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order \ncode 92888 (patients >2yrs). \nFor more information on this test, go to: \n(This link is being provided for \ninformational/educational purposes only.) \nPhysician Comments: \nPERFORMING SITE: \nMI \nQUEST DIAGNOSTICS.MIAMI. I020000MMERCE PARKWAY. MIRAMAR. FL 330254938 Laboratory \nGLEN L. NORM MD FIR/ CI.IA: 1000277334 \nTP \nQUEST DIAGNOSTICS.TAMPA. 4225 E FOWLER AVE TAMPA. FL 33617.2026 Laboratory Duo:tor GLEN L IIORTIN.MD.PIID. CLIA 1000291120 \nCLIENTSERVICES:866.6971378 \nSPECIMEN: MR624132A \nPAGE 5 OF 5 \nQuest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. \nEFTA00621386\n", "char_count": 1473}]}